[Hematopoietic stem cell transplantation for multiple myeloma].
Kanda
Yoshinobu
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D055808:Drug Discovery; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000628:therapy*; D011239:Prednisolone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; D007372:Interferons; D011239:Prednisolone; D008558:Melphalan